Adlai Nortye Ltd. (ANL)

KY — Healthcare Sector
Peers: GOVX  BLRX  THAR  ADAP  APLM  AIMD  OSRH  LPCN  ADTX  ICU 

Automate Your Wheel Strategy on ANL

With Tiblio's Option Bot, you can configure your own wheel strategy including ANL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANL
  • Rev/Share 0.0
  • Book/Share 2.3948
  • PB 0.6765
  • Debt/Equity 1.0683
  • CurrentRatio 1.4123
  • ROIC -1.0414

 

  • MktCap 50603833.0
  • FreeCF/Share -4.8853
  • PFCF -0.9734
  • PE -0.3322
  • Debt/Assets 0.382
  • DivYield 0
  • ROE -0.9895

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade ANL H.C. Wainwright Buy Neutral -- -- June 2, 2025

News

About Adlai Nortye Ltd. (ANL)

  • IPO Date 2023-09-29
  • Website https://www.adlainortye.com
  • Industry Biotechnology
  • CEO Yang Lu
  • Employees 123
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.